CytoCore Inc…
Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
2
Mar |
PadKit(R) Collection System Selected By UCLA School Of Nursing For Its Grant Funded Cervical Cancer StudyCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
CytoCore Inc…
Results of the FDA pivotal clinical trial for the LightTouch™ Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI).
|
14
Jul |
University Of Michigan Study Shows SEQUENOM’s MassARRAY Technology Identifies HPV Infections Missed By Standard Hybridization TestCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Results from a study published by the University of Michigan have shown that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via the most commonly used test for HPV DNA, may actually be infected with the virus at clinically relevant viral loads. PCR-MS detected the presence of high-risk HPV in nearly half (46.
|
19
Jun |
No Improvement In Detecting Cervical Cancer With Addition Of HPV Test In Cervical Screening Programme In The UKCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
An article published Online First and in the July edition of The Lancet Oncology reports that the combination of human papillomavirus (HPV) testing with regular liquid-based cytology (LBC) screening does not improve the detection of cervical cancer compared with LBC screening alone. In the UK, liquid-based cytology (which is a liquid form of the Pap smear test) has replaced the conventional Pap smear test.
|
17
Nov |
New Data On Cancer Diagnostic Presented By Arbor VitaCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Arbor Vita Corporation (AVC), a privately held biopharmaceutical company, presented new data on its rapid, point-of-care prototype HPV test with a high positive predictive value for cervical cancer and pre-cancer. Targeted for use throughout the developing world, this diagnostic test is being developed in partnership with PATH.
|
29
Oct |
Pivotal Study Of SoftPAP Collector Demonstrates Significant Improvements Over Conventional Collection Technique For PAP SampleCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
CytoCore Inc. (OTCBB:CYOE), the developer of cost-effective, screening systems for early detection of gynecological cancers and sexually transmitted diseases, today announced the data analysis from its 703 patient clinical trial on Adequacy, Efficacy and Safety between the SoftPAP® Collector compared to the standard Spatula/CytoBrush Technique.
|
23
Sep |
Ikonisys Introduces Rare-Cell Test Designed To Determine Early Progression To Cervical CancerCategory: Cervical Cancer / HPV Vaccine | Leave a Comment |
Ikonisys, a leading provider of next-generation, cell-based diagnostic solutions, announced today the launch of its clinically-validated, novel cervical cancer test, oncoFISH® cervical. Used in conjunction with the company’s proprietary CellOptics® platform, a robotic microscopy system, oncoFISH cervical provides the physician, while still adhering to current practice guidelines, with an assessment of risk of progression of low grade dysplasia to cancer of the cervix.